ISO 10993 Is Not a Clinical Evaluation Shortcut

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This is not a theoretical issue. It comes up in audits, in CER reviews, and in pre-submission meetings. The confusion is understandable. Both ISO 10993 and the clinical evaluation process address safety. Both are mandatory under MDR. But they operate at different levels of evidence, and they answer different questions.

The problem is that many teams treat biocompatibility as a checkbox. Once the reports are filed, they move on. The clinical evaluation then echoes the ISO 10993 conclusions without interpreting them in the context of actual use. That gap is what reviewers catch.

What ISO 10993 Actually Does

ISO 10993 is a standard for biological evaluation of medical devices. It provides a framework for testing materials and finished devices to assess their interaction with living tissue. The tests cover cytotoxicity, sensitization, irritation, systemic toxicity, and depending on device contact type and duration, other endpoints like genotoxicity, implantation response, hemocompatibility, and carcinogenicity.

The standard helps manufacturers demonstrate that materials are not immediately harmful in controlled laboratory conditions. It is a necessary step. It provides objective, reproducible data. But it operates in a constrained environment. Animal models. In vitro assays. Defined exposure scenarios. Short observation periods in many cases.

ISO 10993 does not tell you what happens when the device is used for years in a diabetic patient with impaired healing. It does not predict how a coating degrades in an inflammatory environment. It does not account for interactions with other implanted devices or concurrent medications.

Why This Creates a Gap

The issue becomes visible when you compare what the two processes deliver. ISO 10993 testing happens early. It often uses materials or prototypes. The testing conditions are standardized and artificial. The results tell you whether the device passes a safety threshold in a laboratory.

Clinical evaluation happens later. It considers the final device, the intended users, the clinical environment, the duration of exposure, the patient population, comorbidities, and everything else that affects real-world outcomes. It must assess whether the device remains safe and performs as intended when all those variables are in play.

Here is where teams go wrong. They write a section in the CER titled